Validity of Bayesian forecasting programme in therapeutic drug monitoring of vancomycin in a surgical intensive care unit: A prospective evaluation

Annals of the Academy of Medicine Singapore

Volumn 25, Issue 4, 1996, Pages 492-495

  Balram, C ^a   Lim, B L ^a   Lee, E J D ^b   Wong, S Y ^c   Ang, B ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

critically ill; MRSA; optimisation; pharmacokinetics; serum concentrations

Indexed keywords

VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

AGED; BAYES THEOREM; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SINGAPORE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0029829983     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Hermans P E, Wilhelm M P Vancomycin. Mayo Clin Proc 1987; 62:901-5
2. Levine J F. Vancomycin: A review Med Clin North Am 1987, 71:1135-45.
3. Wilheim M P. Vancomycin Mayo Clin Proc 1991; 66:1165-70.
4. Pryka R D, Rodvold K A, Erdman S M. An updated comparison of drug dosing methods IV Vancomycin Clin Pharmacokinetics 1991; 20:463-76.
5. Rodvold K A, Pryka R D, Garrison M, Rotschafer J C Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations Ther Drug Monit 1989; 11:269-75
6. Pryka R D, Rodvold K A, Garrison M, Rotschafer J C. Individualising vancomycin dosage regimens, one- versus two-compartment Bayesian models. Ther Drug Monit 1989; 11:450-4.
7. Hurst A K, Yoshinaga M A, Mitani G H, Foo K A, Jellife R W, Harrison E C Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother 1990; 34:1165-71.
8. Lake K D, Peterson C D. A simplified dosing method for initiating vancomycin therapy. Pharmacotherapy 1985; 5:340-4.
9. Louria D B, Kaminski T, Bachman J. Vancomycin in severe staphylococcal infections. Arch Intern Med 1961; 107.225-40
10. Schaad U B, McCracken G H, Nelson J D Clinical pharmacology and efficacy of vancomycin in paediatric patients. J Pediatr 1980; 96 119-26.
11. Sorrell T C, Packham D R, Shanker S, Foldes M, Munro R. Vancomycin therapy for methiallin-resistant staphylococcus uareus. Ann Intern Med 1982; 97 344-50
12. Lisby-Sutch S M, Nahata M C. Dosing guidelines for the use of vancomycin based on its pharmacokinetics in infants. Eur J Clin Pharmacol 1988; 35 637-42
13. Cunha B A, Quintiliani R, Deglin J M, Izard M W, Nightingale C H Pharmacokinetics of vancomycin in anuria. Rev Infect Dis 1981; 3(Suppl):S269-S272.
14. Golper T A, Noonan H M, Elizinga L, Gilbert D, Brummett R, Anderson J L, et al Vancomycin pharmacokinetics, renal handling and nonrenal clearances in normal human subjects Clin Pharmacol Ther 1988; 43:565-70.
15. Matzke G R, McGory R W, Halstenson C E, Keane W F Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984, 25:433-7.